Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

The user has been using dutasteride for 7 months with no improvement in hair loss and is considering switching to finasteride, while also using oral minoxidil. Another user shared their positive experience switching from dutasteride to finasteride, noting less shedding and improved hair condition.

The user shared progress pictures after 7 months of using 3.5 mg of minoxidil and finasteride orally, reporting significant hair regrowth. They noted the need to continue the treatment indefinitely to maintain results, with no side effects experienced.

KX-826 users report increased shedding, with some experiencing more shedding at higher concentrations. Users are discussing where to purchase the product.

CB-03-01 (Breezula) powder for hair loss. Users discuss its availability and seek feedback on its effectiveness.

The user reported progress in hair growth after 7 months using dutasteride, oral minoxidil (2.5 mg once daily), and Nizoral, noting improvements in hair thickness and density. The user experienced no side effects and plans to continue the treatment.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

A 35-year-old shared a 7-day update on their hair transplant, which involved 3,153 grafts performed by Dr. Elif at HLC Ankara, costing 10,000 euros including accommodations. The user has been on finasteride for over 12 years and opted for a partial shave FUE to address hairline recession and temple peaks.

People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.

Veradermics is working on FDA approval for extended-release oral Minoxidil. Approval is expected around 2027.

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

OP shared a 7-year hair density progress update using Minoxidil, Finasteride, and dermarolling. Creatine use was discussed, with mixed opinions on its impact on hair loss.

Pyrilutamide is an experimental hair loss treatment, with users discussing its availability and cost from sources like Anagen Inc, Actifolic, and MinoxidilMax. Some users express concerns about product authenticity and suggest waiting for further trial results to assess its safety and effectiveness.

The user has been using pyrilutamide 0.5% for over 7 weeks, alongside dutasteride, and noticed some hair improvement, particularly at the temples. They plan to continue and possibly try a 1% solution, with no shedding or side effects reported.

Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.

The conversation discusses the use of RU58841 for hair loss, with concerns about its legality in Germany and potential legal consequences. Alternatives like finasteride and dutasteride are mentioned, with some users questioning the effectiveness and safety of RU58841.

A user shared their 7-month progress after a hair transplant, using dutasteride and minoxidil to maintain native hair. The transplant was done in Juarez, Mexico, and the user noted that medication is still necessary to prevent further hair loss.

RU58841 can be absorbed systemically after topical application, but the study did not find immediate hormonal disruption. The study highlights the need for more research on long-term safety and effects of RU58841, as well as the importance of quality control in products from the grey market.

RU58841 from Vantanex is discussed for hair loss treatment. Users share experiences and question its legitimacy.

A user is seeking a pharmacy to compound a topical solution containing Minoxidil, Finasteride, Alfatradiol, Melatonin, Latanoprost, and either RU58841 or Pyrilutamide. They prefer a professional compounding lab over DIY methods.

The user reported significant hair regrowth after seven months using topical minoxidil 5% combined with 0.1% finasteride and weekly micro needling. The community responded positively, noting visible improvement and discussing the effectiveness of topical versus oral finasteride.

The user experienced increased hair shedding after using RU58841, despite initial improvements in scalp condition and appearance. They are considering stopping RU58841 to see if shedding decreases.

Breezula is a potential hair loss treatment, but recent updates suggest it may not be as promising as initially thought. Some users express skepticism about its effectiveness based on past results.

Quitting RU58841 after over two years reduced scalp itching and inflammation, despite concerns about losing hair gains. The user continues using finasteride and oral minoxidil.

A user shared their 7-month progress using oral minoxidil (2.5mg) and recently started finasteride (1mg) daily, reporting significant hair improvement without side effects. They noticed thicker beard growth and some hair thickening at the crown, with no shedding phase yet.

Pelage Pharmaceuticals is starting Phase 3 trials for PP405 in September 2026, with potential market release by 2030. Users discuss various hair loss treatments like minoxidil, finasteride, RU58841, kx, breezula, and gt20029, expressing hope for future hair restoration.

Shiseido's Dermal Sheath Cup (DSC) Hair Multiplication treatment is now available in Japan. Users discuss the treatment's availability and cost.

The conversation discusses an experiment involving hair loss treatments, including the use of Verteporfin, KY19382, dutasteride, oral and topical minoxidil, AHK-Cu, and microneedling. The experiment aims to test the effectiveness of these treatments in promoting hair growth and healing without scarring, with updates planned every few months.

Breezula's phase 3 enrollment for hair loss treatment is complete, but results have not been published, causing skepticism about its progress. Some users express doubt about its future, suggesting it may be reserved for exclusive use.

A user shared progress pictures after 7 months of using finasteride for hair loss, crediting it for noticeable improvement. They also mentioned using minoxidil for 5 years but attributed recent changes to finasteride, with no other supplements or significant side effects reported.